NKTRNasdaqPharmaceutical PreparationsUS GAAP · USD

Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunotherapy medicines for autoimmune disease and cancer. Its pipeline centers on proprietary immunomodulatory drug candidates such as rezpegaldesleukin, NKTR-255 and NKTR-0165, while much of its historical revenue came from collaborations, royalties and licensing arrangements rather than marketed products.

Kysy yhtiöstä
Liikevaihto55,2milj. USD
−43,9 %v/v
Liikevoitto (EBIT)−140milj. USD
−33,2 %v/v
EBIT-marginaali−253,7%
−146,8 %-yks.v/v
Nettotulos−164milj. USD
−37,9 %v/v
Vapaa kassavirta−209milj. USD
−17,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−600−400−2000200milj. USD2020: 153 milj. USD2020: EBIT −425 milj. USD20202021: 102 milj. USD2021: EBIT −446 milj. USD20212022: 92 milj. USD2022: EBIT −376 milj. USD20222023: 90 milj. USD2023: EBIT −264 milj. USD20232024: 98 milj. USD2024: EBIT −105 milj. USD20242025: 55 milj. USD2025: EBIT −140 milj. USD202555−140
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Nektar Therapeutics

Liiketoiminta

Osuus liikevaihdosta
Clinical-stage immunotherapy pipeline15 %

Drug candidates in autoimmune disease and cancer that are being advanced through preclinical and clinical development.

Collaboration and licensing revenue45 %

Upfront fees, milestones and other contingent payments from pharma and biotech partners.

Royalty income20 %

Non-cash and cash royalty streams tied to partnered products developed using Nektar technology.

Manufacturing and supply agreements10 %

Historical product sales from fixed-price manufacturing and supply arrangements with collaborators.

Intellectual property and platform technology10 %

PEGylation and polymer conjugate technologies licensed to partners for drug development and commercialization.

Tuotteet

Raportoitu · osuus liikevaihdosta
99,5%FY2025100 %
  • Non Cash Royalty Revenue Related to Sale of Future Royalties99,5 %
  • License Collaboration and Other Revenue0,5 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Nektar’s direct customers are primarily pharmaceutical and biotechnology collaboration partners that license its technology, fund development, or commercialize partnered assets. Indirectly, its end markets are patients and physicians in autoimmune disease and oncology, but the company currently has no marketed products of its own. Revenue depends on partner decisions, clinical progress and the ability to secure new collaboration agreements.

Pharmaceutical collaboration partners

Large and mid-sized pharma companies that license Nektar’s assets or technology and pay milestones, royalties or supply fees.

Biotechnology development partners

Biotech companies that co-develop or in-license immunology assets and use Nektar’s platform to advance candidates.

Clinical trial ecosystem

Hospitals, investigators and CROs that support patient enrollment, clinical operations and regulatory development.

Future prescribers and patients

Physicians and patients in autoimmune disease and oncology who would use approved products if programs succeed.

Strategia

Nektar is prioritizing advancement of its internal immunotherapy pipeline, especially rezpegaldesleukin, while seeking to rebuild collaboration revenue after the termination of the Eli Lilly agreement. The company is also trying to preserve optionality through new partnerships, because its business model depends on external funding, clinical validation and eventual commercialization support. Capital preservation and pipeline focus are central to its near-term strategy.

Advance rezpegaldesleukin in autoimmune diseaseLyhyt aikaväli

It is the lead asset and the main driver of future value creation and partnering interest.

Secure new collaboration agreementsLyhyt aikaväli

The company lost collaboration-based revenue after the Eli Lilly termination and needs external funding support.

Progress the broader immunotherapy pipelineKeskipitkä aikaväli

Multiple shots on goal reduce dependence on a single asset and improve long-term partnering value.

Conserve capital and simplify operationsLyhyt aikaväli

As a clinical-stage company without marketed products, liquidity and burn management are critical.

Maantiede

Nektar is headquartered in the United States and its business is tied to U.S. clinical development, regulatory oversight and capital markets. Its historical partnered products and royalty streams have also had exposure to Europe and other international markets through global commercialization by partners, but the company itself currently has no disclosed country-level revenue mix. Operationally, the business is concentrated in research, development and collaboration management rather than manufacturing scale.

Riskit

Nektar’s value is highly dependent on clinical success, especially for rezpegaldesleukin, and failure in trials would materially impair partnering prospects and future revenue. The company also faces financing, manufacturing, regulatory and competitive risks typical of clinical-stage biotech, with limited diversification because it currently lacks marketed products. Loss of collaboration revenue or delays in new deals could pressure liquidity and extend dependence on capital markets.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical failure of rezpegaldesleukin1Liquidity and financing risk3Regulatory approval risk4Loss of collaboration revenue2Competitive intensity5Manufacturing and quality risk6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical failure of rezpegaldesleukinVaikutus: KriittinenTodennäköisyys: Kohtalainen

    The company states future success is highly dependent on this lead asset, and most investigational drugs fail before approval.

    Kohdistuu: Autoimmune disease pipeline

  2. Loss of collaboration revenueVaikutus: KorkeaTodennäköisyys: Korkea

    Termination of the Eli Lilly collaboration means no collaboration-based revenue for key drug candidates unless new deals are signed.

    KohdistuuRezpegaldesleukinNKTR-255NKTR-0165NKTR-0166
  3. Liquidity and financing riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company relies on cash, equity financing and partner funding to support R&D until commercialization or new partnerships.

    Kohdistuu: Operating runway and clinical funding

  4. Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Drug development requires lengthy FDA and global review, and approval is not assured even after positive data.

    Kohdistuu: All pipeline assets

  5. Competitive intensityVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Larger pharma and biotech companies may have superior resources, faster development programs and stronger commercialization capabilities.

    Kohdistuu: Autoimmune and oncology immunotherapy

  6. Manufacturing and quality riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Contract manufacturers must produce biologics at required quality and scale to support trials and future supply.

    Kohdistuu: Clinical supply chain

Kysy Clarifolta: Nektar Therapeutics

Kirjanpito

Harkinnanvaraiset erät
ASC 606 collaboration revenue recognition

Upfront fees and milestones are recognized over time or upon achievement, so timing can shift reported revenue materially.

Vaikutus: Affects license, collaboration and other revenue

Non-cash royalty revenue and non-cash interest expense

Royalty rights previously sold create accounting entries that do not affect cash flow but do affect the income statement.

Vaikutus: Can distort earnings versus operating cash generation

Asset impairment and lease accounting

Office and life sciences lease market conditions, sublease assumptions and asset recoverability can drive impairment charges.

Vaikutus: Can materially affect operating results and balance sheet values

Collaborative arrangement presentation

Some partner payments may be recorded as reductions of R&D or G&A rather than revenue depending on ASC 808 analysis.

Vaikutus: Changes gross revenue and expense presentation

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Context Therapeutics Inc.

CNTX · Pharmaceutical Preparations

Kezar Life Sciences, Inc.

KZR · Pharmaceutical Preparations

Aclaris Therapeutics, Inc.

ACRS · Pharmaceutical Preparations

Eledon Pharmaceuticals, Inc.

ELDN · Pharmaceutical Preparations

Regen BioPharma Inc

RGBPP · Pharmaceutical Preparations

Monopar Therapeutics

MNPR · Pharmaceutical Preparations

Päivitetty: 24.9.2026